Parkside Financial Bank & Trust Mirati Therapeutics, Inc. Transaction History

Parkside Financial Bank & Trust

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	SELL	$41.99 - $62.38 $2,771 - $4,117	-66 Reduced 50.38%	65 $3,000
Q3 2023 Nov 13, 2023	BUY	$27.8 - $45.35 $3,641 - $5,940	131 New	131 $5,000
Q1 2023 May 04, 2023	BUY	$36.54 - $54.26 $1,461 - $2,170	40 Added 571.43%	47 $1,000
Q4 2022 Feb 13, 2023	SELL	$41.27 - $98.62 $453 - $1,084	-11 Reduced 61.11%	7 $0
Q3 2022 Nov 01, 2022	BUY	$59.5 - $86.7 $654 - $953	11 Added 157.14%	18 $1,000
Q2 2022 Jul 13, 2022	SELL	$39.16 - $88.71 $1,409 - $3,193	-36 Reduced 83.72%	7 $0
Q1 2022 May 13, 2022	BUY	$75.82 - $150.97 $3,260 - $6,491	43 New	43 $4,000
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $4,620 - $6,660	-35 Closed	0 $0
Q3 2021 Oct 29, 2021	BUY	$132.13 - $177.45 $528 - $709	4 Added 12.9%	35 $7,000
Q2 2021 Aug 06, 2021	BUY	$144.0 - $179.73 $4,464 - $5,571	31 New	31 $5,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Parkside Financial Bank & Trust, based on Form 13F filings with the SEC.

Stay updated on Parkside Financial Bank & Trust with notifications on news.